Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 04 2022 - 8:00AM
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative, disease-modifying therapies for neurodegenerative
diseases, today announced that Richard Peters, M.D., Ph.D.,
President and Chief Executive Officer, will present at the H.C.
Wainwright BioConnect Conference, being held virtually January
10-13, 2022.
The presentation will be available on-demand via the conference
portal and through the Company's website
at www.yumanity.com/events beginning at 7 a.m. EST,
January 10.
About Yumanity TherapeuticsYumanity
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to accelerating the revolution in the treatment of
neurodegenerative diseases through its scientific foundation and
drug discovery platform. The Company’s most advanced product
candidate, YTX-7739, is in clinical development for Parkinson’s
disease. Yumanity’s drug discovery platform enables the Company to
rapidly screen for potential disease-modifying therapies by
overcoming the toxicity of misfolded proteins associated with
neurogenerative diseases. Yumanity’s pipeline consists of
additional programs focused on Lewy body dementia, multi-system
atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s
disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s
disease. For more information, please
visit www.yumanity.com.
Investors:Burns McClellan, Inc.Lee
Rothlroth@burnsmc.com (212) 213-0006
Media:Burns McClellan, Inc.Robert Flamm,
Ph.D.rflamm@burnsmc.com(212) 213-0006
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jul 2023 to Jul 2024